Abeona Therapeutics Inc
ABEO
Company Profile
Business description
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Contact
6555 Carnegie Avenue
4th Floor
ClevelandOH44103
USAT: +1 646 813-4701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
136
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
We expect the strong earnings momentum at this company to continue, with shares looking fairly valued.
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.90 | 39.90 | -0.44% |
| CAC 40 | 7,854.61 | 67.63 | 0.87% |
| DAX 40 | 23,674.53 | 315.35 | 1.35% |
| Dow JONES (US) | 46,142.42 | 124.10 | 0.27% |
| FTSE 100 | 9,228.11 | 19.74 | 0.21% |
| HKSE | 26,544.85 | 363.54 | -1.35% |
| NASDAQ | 22,470.72 | 209.40 | 0.94% |
| Nikkei 225 | 45,303.43 | 513.05 | 1.15% |
| NZX 50 Index | 13,120.03 | 108.35 | -0.82% |
| S&P 500 | 6,631.96 | 31.61 | 0.48% |
| S&P/ASX 200 | 8,745.20 | 47.70 | -0.54% |
| SSE Composite Index | 3,831.66 | 44.68 | -1.15% |